Skip to main content
OpenTrials
Completed

NCT Number: NCT04170140

Study on Prescribers' Knowledge and Understanding of Safety Messages Following Dengvaxia® Product Information Update

The primary objective of the study is to evaluate the effectiveness of additional risk minimization measures material by assessing the knowledge and understanding of healthcare professionals regarding the key safety messages provided in the material.

The secondary objective of the study is to evaluate if healthcare professionals know Dengvaxia product information, namely, age indication and contraindications.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Dengue Virus Infection Arbovirus Infections Dengue Flaviviridae Infections Flavivirus Infections Hemorrhagic Fevers, Viral Infections Mosquito-Borne Diseases RNA Virus Infections Vector Borne Diseases Virus Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Real World Evidence Solutions IQVIA

La Defense, France

About this study

The study is a cross-sectional Survey. Study data are collected through a questionnaire.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthcare professionals who are current or past prescribers of Dengvaxia

Exclusion criteria

  • Healthcare professionals who have never prescribed Dengvaxia
  • Healthcare professionals who may have a conflict of interest with the survey (i.e. Healthcare professionals employed by regulatory bodies, pharmaceutical industries)
  • Healthcare professionales who have participated in testing the questionnaire for comprehensibility, consistency and the appropriateness of medical terms

The above information is not intended to contain all considerations relevant to participation in the survey.

Treatment and study plan

No intervention

Other

Questionnaire

Primary outcomes

  1. Healthcare professionals' knowledge and understanding of key safety messages provided in risk minimization measures materials

    Time frame: Day 0

    Knowledge and understanding of key safety messages are assessed through a questionnaire

Secondary outcomes

  1. Healthcare professionals' knowledge of Dengvaxia product information

    Time frame: Day 0

    Knowledge of Dengvaxia product information (age indication and contraindications) is assessed through a questionnaire

Sponsors and collaborators

Lead sponsor

Sanofi Pasteur, a Sanofi Company

Industry

Registry information

Official study title

A Cross-sectional Survey to Evaluate Prescribers' Knowledge and Understanding of Safety Messages Following Dengvaxia® Product Information Update

Acronym: DNG00042

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Nov 20, 2019
Registry last updated
Sep 18, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.